Metabolic Syndrome in Inpatients Treated With Clozapine
J Clin Psychiatry 2011;72(6):872-873 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Letter to the Editor
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
I read with interest the important study by Dr Bai and coauthors of metabolic factors and weight gain in schizophrenia patients treated with clozapine. They found that baseline body mass index (BMI) and BMI change over time were associated with metabolic syndrome and 4 metabolic parameters, with the notable exceptions of hyperglycemia and diabetes mellitus, which were related to duration of clozapine treatment rather than weight gain.
Metabolic syndrome in schizophrenia during antipsychotic treatment is a highly relevant and worrisome topic in relation to at least some of the antipsychotics.